AgomAb Therapeutics NV American Depositary Shares (AGMB)
- Headquarters
- United States
- Employees
- 62
- Market Cap
- $628M
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
SentiSense also tracks daily options readings for AgomAb Therapeutics NV American Depositary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
AgomAb Therapeutics NV American Depositary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.